US 9,809,858 B2
O-glycan pathway ovarian cancer signature
Johnathan M. Lancaster, Tampa, FL (US); Douglas C. Marchion, Seminole, FL (US); and Yin Xiong, Tampa, FL (US)
Assigned to H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US)
Appl. No. 14/387,321
Filed by H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., Tampa, FL (US)
PCT Filed Apr. 5, 2013, PCT No. PCT/US2013/035470
§ 371(c)(1), (2) Date Sep. 23, 2014,
PCT Pub. No. WO2013/152301, PCT Pub. Date Oct. 10, 2013.
Claims priority of provisional application 61/620,757, filed on Apr. 5, 2012.
Prior Publication US 2015/0080249 A1, Mar. 19, 2015
Int. Cl. C12Q 1/68 (2006.01); G01N 33/574 (2006.01)
CPC C12Q 1/6886 (2013.01) [G01N 33/57449 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/52 (2013.01)] 9 Claims
OG exemplary drawing
 
1. A method for determining the prognosis of a patient with ovarian cancer, comprising
a) assaying a biological sample from the subject for the expression level of at least ten (10) O-glycan biosynthesis pathway (OGBP) genes selected from the group consisting of B3GALT1, B3GALT2, B3GALT4, B3GALT5, B3GNT6, B4GALT1, B4GALT2, B4GALT3, C1GALT1, GALNT1, GALNT10, GALNT11, GALNT12, GALNT13, GALNT14, GALNT2, GALNT3, GALNT4, GALNT5, GALNT6, GALNT7, GALNT8, GALNT9, GALNTL1, GALNTL2, GALNTL4, GALNTL5, GCNT1, GCNT2, GCNT3, ST3GAL1, ST3GAL2, ST6GALN, and WBSCR17;
b) comparing the expression levels of the genes to control values to produce a gene profile; and
c) analyzing the gene profile to calculate an OGBP risk score using standard statistical analysis, and
d) optimally debulking the ovarian cancer if the patient has a high OGBP score, and not debulking or only suboptimally debulking the ovarian cancer if the patient has a low OGBP score.